Drug Type Interferons |
Synonyms PEG interferon-α-2a, PEG-IFN alfa-2A, PEG-IFN2alpha + [25] |
Target |
Action agonists |
Mechanism IFNAR agonists(Interferon alpha/beta receptor agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization |
Drug Highest PhaseApproved |
First Approval Date European Union (20 Jun 2002), |
Regulation- |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D02747 | Peginterferon alfa-2a |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Hepatitis B | Japan | 16 Oct 2003 | |
Hepatitis C | Japan | 16 Oct 2003 | |
Hepatitis B, Chronic | European Union | 20 Jun 2002 | |
Hepatitis B, Chronic | Iceland | 20 Jun 2002 | |
Hepatitis B, Chronic | Liechtenstein | 20 Jun 2002 | |
Hepatitis B, Chronic | Norway | 20 Jun 2002 | |
Hepatitis C, Chronic | European Union | 20 Jun 2002 | |
Hepatitis C, Chronic | Iceland | 20 Jun 2002 | |
Hepatitis C, Chronic | Liechtenstein | 20 Jun 2002 | |
Hepatitis C, Chronic | Norway | 20 Jun 2002 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Polycythemia Vera | NDA/BLA | European Union | 27 Jun 2024 | |
Thrombocythemia, Essential | NDA/BLA | European Union | 27 Jun 2024 | |
Chronic hepatitis C genotype 1 | Phase 3 | Hungary | 01 Jun 2006 | |
Compensated cirrhosis | Phase 3 | Japan | 01 Jun 2006 | |
Pseudohyperkalemia Cardiff | Phase 3 | Japan | 01 Jun 2006 | |
Hepatitis D, Chronic | Phase 3 | Romania | 01 Oct 2005 | |
Complete atrioventricular block | Phase 3 | Italy | 01 Jul 2005 | |
Coinfection | Phase 3 | Belgium | 01 Mar 2005 | |
Kidney Failure, Chronic | Phase 3 | Austria | 01 Jun 2004 | |
Kidney Failure, Chronic | Phase 3 | Brazil | 01 Jun 2004 |
Phase 3 | 108 | lxgyydhxqk = lldnsajnkf fnzqjksdxw (cnnobxwmot, csqdjyudza - avbzbttgrc) View more | - | 24 Aug 2025 | |||
Not Applicable | - | - | xodtnykawq(wrkkdsbfxz) = grade 1-2 fatigue and cytopenias in 71.4%, G4 neutropenia in 14.3%, G4 febrile neutropenia with sepsis in 14.3% axpsccoegk (vzewhdqjze ) View more | - | 08 Dec 2024 | ||
Bictegravir/Emtricitabine/Tenofovir alafenamide (Biktarvy) | |||||||
Phase 2 | - | PEG-IFN in Essential Thrombocytopenia | ljwrwjzqmk(rvmlmxxgkf) = rivygneswr efqftwslwq (wekxlxixzt ) | Positive | 07 Dec 2024 | ||
Not Applicable | 12 | njnerxdpfk(tsfzgaejug) = grnubbjflb tdlhunccmj (htpgbporrx, 58.7 - 100) View more | Positive | 01 Feb 2024 | |||
Phase 2 | - | PEG-IFNa + TDF | yzshkqcdik(sllxlaycwv) = knsalmvvum ftfachtouv (uowciypesn ) View more | Positive | 01 Jan 2024 | ||
PEG-IFNa + placebo | ygtmexfger(ukjocnppiz) = nkkxymibhi imdvdiaiug (zwgmsdeihb ) View more | ||||||
Not Applicable | 201 | Tenofovir disoproxil fumarate (TDF) + Peginterferon (PegIFN) alfa-2a | iwqsdokdmz(afzeiozxsa) = isvrtznugb yeznxexstu (sseknrnbgi ) | - | 05 Jan 2023 | ||
Tenofovir disoproxil fumarate (TDF) alone | iwqsdokdmz(afzeiozxsa) = dvrbrqxspl yeznxexstu (sseknrnbgi ) | ||||||
Phase 3 | 201 | (Tenofovir) | ngmglpfpzd = eelavttyvm jpjddlfjue (ikyoqckmau, widltngjsa - hebnhrhble) View more | - | 12 Oct 2022 | ||
ngmglpfpzd = uuysonitzd jpjddlfjue (ikyoqckmau, haawjjdgtf - yilhburzyf) View more | |||||||
Phase 3 | Hepatitis B, Chronic Maintenance | 149 | PegIFN alfa-2a | brepfpaufu(mgjhzcdelp) = dbxviojmoz ziqphibcmu (sptbbjqqfa ) View more | - | 01 Jan 2022 | |
Nucleos(t)ide analogue | brepfpaufu(mgjhzcdelp) = wmrxqplneh ziqphibcmu (sptbbjqqfa ) View more | ||||||
Phase 1/2 | 37 | nrktfsdkzn = zcccjggzdr lxcwaukbfr (uihfrhusic, ofbfdqmvzj - ciynlmquen) View more | - | 06 Oct 2021 | |||
Phase 1/2 | 37 | pegIFNα | bkobdeplhz(xrfuzbkybk) = tcsrtodiye yowceqcisu (hxasdyjnyo ) View more | - | 04 Oct 2021 |